pharmaceuticals

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) fell 6 percent on Wednesday and remain within striking distance of its 52-week low of $88.50. Activist investor and Valeant shareholder Bill Ackman wrote a letter to Valeant's CEO saying his reputation is "at grave risk"...

Investors have been anxiously awaiting earnings report from pharmaceutical giants to ease ongoing concerns. Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Co (NYSE: BMY), and Merck & Co., Inc. (NYSE: MRK) reported their quarterly Tuesday morning results. Shares of all three names were...

Wendy Lam of Oppenheimer maintained an Outperform rating on shares of Gilead Sciences, Inc. (NASDAQ: GILD) and Perform rating on shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Lam noted that Gilead's two core franchises offer a "durable foundation" of substantial...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were lower by more than 6 percent Thursday and now down nearly 30 percent over the past three months. Valeant announced on Wednesday it has responded to government inquiries into its drug pricing practices. Sumant Kulkami of Bank of...

David Buck of Northland Capital Markets initiated coverage of Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Mallinckrodt PLC (NYSE: MNK), and Shire PLC (ADR) (NASDAQ: SHPG) with Outperform ratings. Buck is positive on the long-term revenue prospect of the three names. Buck noted all three...

Drug pricing remains a concern within the pharmaceutical sector. Liav Abraham of Citi commented in a note on Monday that recent negative headlines are "unhelpful" to investor sentiment. Abraham suggested investors can "hide" in Allergan PLC (NYSE: AGN) and Teva Pharmaceutical Industries Ltd (ADR...

Gbola Amusa, Chardan Capital Markets' head of healthcare research, commented in a note on Monday that investors should be "more selective" in the biotech space. As such, the analyst downgraded shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to Neutral from Buy with an unchanged $565 price...

After markets posted record highs in 2014, many began to worry about a market correction in the coming year as rates rise and the tech sector cools off. This first week of 2015, oil prices brought U.S. markets sharply lower, reminding traders that the good times may not last forever. While some...

While Gilead Sciences, Inc. (NASDAQ: GILD) stood out among the leading biotechs and emerging pharmaceuticals as the only one that saw a notable rise in short interest between the November 14 and November 28 settlement dates. During that time, short sellers fled from Amgen, Inc. (NASDAQ: AMGN) and...

The pharmaceutical sector continued its ongoing consolidation recently as the Swiss drug company Roche Holdings (OTC: RHHBY) came to an agreement with InterMune (NASDAQ: ITMN) to make a cash purchase of the American biotech corporation for $8.3 billion. Roche said that a tender offer for the...

For all the talk and, yes, hype about the marijuana industry's so-called “green rush,” the big pharmaceutical companies appeared to be giving cannabis-based treatments the cold shoulder because of federal laws outlawing marijuana. Given the legal, political and cultural inroads...

With the death toll from West Africa’s Ebola outbreak reaching close to 1,000, serious interest is being taken into researching compounds that could both prevent outbreak and help those infected. Until recently, Ebola was a pretty rare disease, Dr. Jim Wilson told Benzinga, and the...